NEW YORK, Feb. 11 - Deltagen has dipped its toes deeper into drug-development waters with its proposed acquisition of Bristol-Myers Squibb's Pharma Research Labs division.
 
The acquisition, which will cost roughly $23.5 million in stock, gives Deltagen the keys to a small molecule-drug discovery firm.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.